SUNESIS PHARMACEUTICALS INC. SNSS Cash Flow

Sunesis pharmaceuticals inc. (SNSS)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities
Net loss
-23,245	-23,330	-24,040	-24,603	-25,202	-26,615	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-36,167	-37,771	-38,023	-41,064	-39,131	-37,634	-36,676	-26,421	-34,725	-37,557	-43,002	-48,856	-41,138	-37,547	-34,598	-31,473	-41,262	-41,651	-43,951	-48,639	-36,257	-35,905	-20,141	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
1,651	1,749	1,728	1,900	2,158	2,637	2,794	2,658	3,042	3,033	3,466	4,055	4,225	4,791	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Accretion of investment discounts and depreciation
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	5,393	4,791	4,440	3,885	3,602	3,443	2,907	2,724	0	0	0	-	-	-	-
Depreciation and amortization
-	-	-	-	-	-	8	9	9	9	10	9	10	11	11	11	19	27	35	40	35	29	22	19	18	20	23	27	30	31	33	34	41	56	0	0	0
Amortization of debt discount and debt issuance costs
78	116	160	203	186	192	196	209	239	269	296	314	315	359	309	261	213	135	173	225	295	367	433	498	561	621	667	602	510	400	0	0	0	-	-	0	0
Write-off debt discount upon note repayment
-	-	-	-	-	-	-	-	-	-	-	-	-	27	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3,543	-13,673	-10,274	-8,740	-3,892	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
(Decrease) increase in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,783	-5,089	-5,482	-7,509	-12,099	-1,489	-2,616	5,878	0	0	0
Foreign exchange gain on marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	142	290	224	12	82	0	0	0	-	0	0	0
Changes in operating assets and liabilities:
Other non-cash items
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Prepaids and other assets
294	294	812	568	16	-1,063	-1,183	-631	862	1,921	1,753	1,380	13	85	44	-333	-776	-660	-473	46	370	43	284	153	-44	-489	-687	-654	-717	98	-35	242	336	343	0	0	0
Accounts payable
1	-602	-507	-861	-177	-304	-264	-724	-1,609	-174	-985	-482	66	-582	736	477	460	-724	1,018	1,769	1,110	2,224	-687	-1,596	-516	875	272	1,716	658	-580	860	64	253	242	0	0	0
Accrued clinical expense
180	21	-100	-27	-150	-267	-121	-257	-781	-667	-870	-1,197	-834	-520	-274	-243	-40	-1,158	-1,712	-1,689	-1,412	-1,638	-1,217	1	-703	-699	175	-45	1,776	3,079	1,901	1,581	965	796	0	0	0
Accrued compensation
69	42	-9	-86	-185	-497	-395	-217	-193	-560	94	59	126	394	-4	-132	-100	-681	-504	-43	158	568	693	289	193	254	225	219	98	191	58	22	87	261	0	0	0
Other accrued liabilities
-147	183	-1,372	-932	-590	-622	586	464	17	-63	-592	-834	244	-1,062	-981	-2,136	-1,081	-186	-1,134	18	807	1,674	2,267	2,579	278	-76	879	-403	1,033	522	479	1,239	674	516	0	0	0
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-1,831	-2,441	-2,441	-2,441	-2,441	-2,687	-2,930	-3,174	-3,418	-4,552	-5,687	-6,821	-7,956	-7,955	-7,956	0	0	0	-	-	-	-	-	-	-	-
Net cash used in operating activities
-21,816	-22,185	-24,943	-24,965	-23,967	-24,404	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-8,651	-29,085	-25,419	-22,836	0	0	0
Cash flows from investing activities
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-35,904	-36,962	-38,266	-39,067	-37,845	-38,731	-38,470	-41,362	-43,349	-43,181	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	48	0	0	0	-	-	-	-	-	-	-	-	15	0	0	0
Purchases of marketable securities
0	-	-	-	-	-	-	-	-	-	-	-	-	35,530	33,717	74,178	71,255	35,683	28,868	28,456	38,102	42,463	42,239	40,583	30,641	26,894	54,920	77,528	67,473	67,608	53,128	33,239	44,244	52,082	0	0	0
Proceeds from maturities of marketable securities
0	-	-	-	-	4,780	4,507	7,622	19,686	29,774	27,559	-9,239	-15,552	20,531	28,499	69,764	76,113	36,930	39,085	40,986	37,386	45,836	42,043	51,922	58,982	59,110	66,385	52,311	48,606	46,226	47,946	56,308	53,313	56,241	0	0	0
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-7,568	-14,999	-4,728	-4,414	4,858	1,247	10,217	12,505	-741	3,325	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities
0	-	-	-	-	4,780	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-5,183	23,104	9,100	4,178	0	0	0
Cash flows from financing activities
Proceeds from notes payable, net of issuance cost
-	-	-	-	-	-	-	-	-	-	-	-	-	15,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Principal payments on notes payable
-	7,500	0	0	0	-	-	-	-	-	-	-	-	7,983	7,983	830	830	1,642	4,061	6,425	8,737	9,356	9,148	8,946	8,749	7,182	0	0	0	-	-	-	-	-	-	-	-
Payoff of notes payable and final payment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of financing fees and debt issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	266	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of convertible preferred stock offering, net
-	12,533	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock, net
-	32,022	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	40,024	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock through controlled equity offering facilities, net
-	-	-	-	-	6,040	0	0	0	-	-	-	-	-	-	-	-	18,125	27,691	27,241	19,577	14,292	0	0	0	-	-	-	-	-	-	-	-	4,053	0	0	0
Proceeds from exercise of stock options and stock purchase rights
-	-	-	-	-	303	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of warrants, stock options and stock purchase rights
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	533	617	1,570	1,678	1,961	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	31,084	33,131	32,018	32,626	38,061	42,184	24,247	22,398	12,520	46,921	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of warrants and stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Proceeds from exercise of warrants, stock options and stock purchase rights
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	584	253	100	68	0	0	0
Net cash provided by financing activities
-	43,035	43,094	22,222	23,375	6,343	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	43,565	10,150	11,687	13,746	0	0	0
Net increase in cash, cash equivalents and restricted cash
663	4,565	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Conversion of preferred stock to common stock
-	21,762	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Right-of-use assets obtained in exchange for new operating lease liabilities
-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	9,895	18,921	2,122	2,225	-12,388	-18,830	-10,976	-10,855	5,074	4,700	-4,006	-6,459	-31,570	7,065	-925	20,156	37,799	181	-19,893	-5,138	7,273	5,629	29,731	4,169	-4,632	-4,912	0	0	0
Fair value of warrants issued in connection with notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	536	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Legal expenses accrued as cost of equity financing
-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-